Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B3
Source: 0001062993-25-010580
Chunk: 81

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B3
Chunk 81
---
 March 31, 2024. The increase is primarily due to increased spending on research and development activities for our SKNJCT-003 study and trials and increased general and administrative expenses related to our recent initial public offering and resulting U.S. reporting obligations.

Cash flows provided by financing activities

Cash flows provided by financing activities for the three months ended March 31, 2025, were $3,759,101 due to proceeds from issuance of common shares and warrants, net of offering costs from the Regulation A Offering. The Company did not have any financing activities for the three months ended March 31, 2024.

|                                       |     | For the year ended December 31, 
                            2024 
                               $ |   |     |       2023 
          $ |   |
|:--------------------------------------|:----|--------------------------------:|:--|:----|-----------:|:--|
| Cash used in operating activities     |     |                     (10,247,231 | ) |     | (4,158,264 | ) |
| Cash provided by financing activities |     |                      12,692,216 |   |     |  5,609,950 |   |
| Net change in cash during the year    |     |                       2,444,985 |   |     |  1,451,686 |   |
| Cash, beginning of the year           |     |                       1,719,338 |   |     |    267,652 |   |
| Cash, end of the year                 |     |                       4,164,323 |   |     |  1,719,338 |   |

<div align='center'>- 49 -</div>

Cash flows used in operating activities

Cash flows used in operating activities for the year ended December 31, 2024 were $10,247,231 compared to cash flows used in operating activities of $4,158,264 for the year ended December 31, 2023. The increase is primarily due to increased spending on research and development and general and administrative expenses.

Cash flows provided by financing activities

Cash flows provide by financing activities for the year ended December 31, 2024, were $12,692,216 compared to cash flows provided by financing activities of $5,609,950 for the year ended December 31, 2023. The increase is primarily due to increased proceeds from the issuance of convertible notes and proceeds from the issuance